The State of Play

Rehabilitation, assistive, and prosthetic robotics has cleared every traditional gate to mainstream adoption -- regulatory approval across three regions, operational insurance reimbursement, and clinical evidence from multi-centre RCTs -- yet remains a leading-edge practice confined to well-resourced institutions and individually funded home users. The technology works: AI-controlled exoskeletons train gait in stroke and spinal cord injury patients (though meta-analysis evidence shows no superiority to conventional therapy for ambulatory function), neural-interface prosthetics decode motor intent with over 96% accuracy, and brain-computer interfaces are producing clinically meaningful results in chronic stroke recovery. China's regulatory approval of Neuracle Medical Technology's implantable BCI for hand movement (March 2026) marks the first commercial BCI clearance for prosthetic control, expanding the field beyond US institutions. Three major Medicare Advantage insurers now cover personal exoskeletons, reaching roughly 16 million beneficiaries, with Good Shepherd Rehabilitation achieving 500,000+ cumulative steps in Wandercraft Atalante X deployment. But the gap between regulatory clearance and real-world scale remains wide. Ekso Bionics, the category's largest institutional vendor with 400-plus facility deployments, posted a 29% revenue decline in 2025, a $11.7M net loss, and is exiting medical robotics through a merger with an AI infrastructure firm. By May 2026, Ekso's formal withdrawal formalized with SEC filing confirming business combination closing and shareholder dilution, consolidating evidence of market viability challenges despite technical capability. Leading exoskeleton researchers identified critical unverified claims in sim-to-real ML transfer research in 2026, highlighting persistent technical maturity gaps. The defining tension is not whether these systems deliver clinical value -- the evidence is strong -- but whether the economics, implementation complexity, and engineering claims can support deployment at scale beyond the vanguard.

The exoskeleton vendor landscape is fragmenting. Ekso Bionics reported $12.4M in 2025 revenue against an $11.7M net loss, issued a going-concern warning, and completed merger into AI infrastructure firm (ChronoScale Corporation) in May 2026—effectively exiting medical robotics despite holding 400+ facility deployments. Q1 2026 SEC filings (April 28) documented further deterioration: revenue $2.1M (YoY decline), net loss $6.9M, and explicit going-concern language citing cash runway only to early Q3 2026. Lifeward (formerly ReWalk) is moving in the opposite direction, commercialising the ReWalk 7 with cloud connectivity and acquiring Skelable's AI-powered upper-body exoskeleton for stroke rehabilitation. Wandercraft has deployed nearly 100 Atalante X units across the US, Europe, and Brazil, with Good Shepherd Rehabilitation (Philadelphia) reaching 500,000+ cumulative steps in 2026 (documented at ASIA 2026 conference with 13-year longitudinal safety data showing zero fractures in German cohort since 2018). Six FDA/CE-approved commercial exoskeletons remain on the market, but vendor economics remain precarious. Clinical partnerships are expanding: Lifeward partnered with Shirley Ryan AbilityLab (ranked #1 US rehabilitation hospital) in March 2026 to expand ReWalk Personal access and integration into clinical workflows.

Reimbursement has reached meaningful operational scale. Medicare set a $94,617 lump-sum payment for personal exoskeletons in January 2024; by April 2026, Aetna, Humana, and UnitedHealthcare together grant coverage to approximately 16 million Medicare Advantage beneficiaries, with payment processing under 30 days. An Administrative Law Judge ruling in June 2025 established legal precedent for medical necessity. These milestones converted coverage from policy aspiration to operational reality, yet adoption remains constrained by implementation barriers rather than access.

Brain-computer interfaces have reached a regulatory inflection point. China's National Medical Products Administration approved Neuracle Medical Technology's implantable BCI for hand movement control in March 2026—the world's first commercial BCI clearance for prosthetic function, validated across 32 patients at 11 Chinese hospitals including Fudan Huashan. May 2026 evidence consolidates BCI maturity: CorTec's Brain Interchange platform demonstrated dual capability (therapeutic cortical stimulation for stroke recovery plus thought-controlled computer use) on same implanted device in NIH-funded UW trial; BrainCo's non-invasive commercial prosthetics achieved cost parity (1/5 to 1/7 of Western devices) across 35+ countries with 2,000 units fitted in China and government policy reimbursement support; Paradromics gained IDE approval for BCI speech-restoration trial across multiple academic centers (UC Davis, MGH, U. Michigan). BrainGate typing neuroprosthesis achieved 110 characters/minute (22 words/minute) with 1.6% error rate in home-use trials, and a peer-reviewed meta-analysis of BCI-assisted stroke rehabilitation showed significant improvement in upper-limb motor function across 642 patients. Neural-interface prosthetics are advancing: machine-learning-driven RPNI control has achieved over 96% accuracy in real-time functional tasks, and osseointegrated mechanoneural prostheses have demonstrated improved walking and embodiment in clinical trials. However, these remain early-deployment achievements. Average device costs of $42,800 and documented user concerns about reliability, safety, and social acceptance keep adoption narrow. Critical assessment: A 2026 multicenter RCT showed exoskeleton-assisted gait training was NOT superior to conventional rehabilitation for primary ambulatory function outcomes, though secondary improvements in lower-limb strength were observed—challenging claims of broad therapeutic superiority. Soft exoskeleton RCTs (April-May 2026) confirm efficacy in Parkinson's (stride length +0.15m, ankle mobility improved) though evidence limited to pilot-stage designs. Leading exoskeleton researchers identified unverified claims in sim-to-real transfer research, with reported results violating physiological limits and algorithmic implementations unavailable for verification, indicating persistent maturity gaps in ML-driven control systems.

• 2017: First breakthroughs in sensory-feedback prosthetics (Johns Hopkins APL modular limb), early FDA regulatory approvals for medical exoskeletons (ReWalk, Indego, Ekso GT, HAL), and emergence of affordable 3D-printed alternatives. Clinical studies began validating exoskeleton-assisted gait training for stroke and spinal cord injury recovery. Institutional adoption accelerated through partnerships with rehabilitation centers.
• 2018: Ekso Bionics reported 240+ clinical centers deploying EksoGT globally with 100M patient steps; closed-loop sensory prosthetics achieved 96.7% accuracy in neural control. First human surgical trials of agonist-antagonist myoneural interfaces (AMI) showed improved proprioceptive feedback. Home-use studies revealed sensory feedback transformed user adoption from sporadic to frequent use. Peer-reviewed assessments confirmed clinical efficacy but identified persistent barriers: high cost, reimbursement gaps, device usability challenges (donning/doffing, portability), and heterogeneous patient needs.
• 2019: Insurance reimbursement breakthrough with Cigna policy change to case-by-case review and 17+ successful Blue Cross Blue Shield authorizations for ReWalk systems; named patients began receiving exoskeletons for home use. Ekso Bionics released EksoNR with FDA/CE clearance and smart assistance software, demonstrating continued product maturation. Clinical trials confirmed efficacy: 12 SCI patients using ReWalk achieved functional ambulation after ~45 sessions, with one non-walker becoming independent; home-use study of sensory-enabled prosthesis showed improved psychosocial outcomes and user engagement. However, critical assessments highlighted persistent real-world barriers: exoskeleton weight, supervision requirements, limited outdoor functionality, and cost/complexity that confined deployment to institutional and affluent individual settings.
• 2020: Neural-interface prosthetics advanced with high-DOF AI-decoding (15 degrees of freedom) and long-term home use studies confirming that osseointegrated neuromusculoskeletal prostheses improved psychosocial outcomes and daily-life integration in 2-6 year chronic users. Exoskeleton deployment expanded: acute-stroke inpatient trials (44 patients across multiple centers) showed robotic training doubled walking distance vs. standard care; ReWalk energy-efficiency vs. KAFO comparisons (13 SCI patients) demonstrated technical advantage but revealed user satisfaction friction. The 30-year review of peripheral nerve interfaces identified dual advancement pathways yet confirmed barriers to clinical market translation. Cost-effectiveness analysis emerged as the critical adoption bottleneck—healthcare systems required economic justification for widespread integration, constraining growth despite proven clinical efficacy. By year-end 2020, deployment remained concentrated in well-funded rehabilitation institutions with insurance coverage or personal resources.
• 2021: Commercial exoskeleton activity accelerated with multimodal trials showing mixed clinical signals. Multi-center RCTs with 130+ stroke patients (BEAR-H1) and 75+ patients (o-RAGT) demonstrated non-inferiority to conventional training rather than superiority, while SuitX Phoenix (40 SCI patients) confirmed efficacy and high user satisfaction. Ekso Bionics booked 20 EksoNR units globally and expanded into long-term acute care, signaling sustained commercial momentum. Neural-interface prosthetics achieved multimodal integration—combining touch, kinesthesia, and motor control—approaching able-bodied grasping function. Critical assessments documented persistent real-world barriers: cognitive load trade-offs in mentally demanding tasks, ethnographic studies showing adoption variability tied to psychosocial factors, and fragmented neuroprosthetics development hampering sensory restoration progress. Market analysis confirmed innovation barriers across planning, conceptualization, and adoption phases. Year-end 2021 showed technical maturity with commercial scaling, yet practical deployment remained confined to institutional settings and well-resourced individual cases.
• 2022-H1: Exoskeleton vendors demonstrated sustained institutional adoption: EksoNR expanded to 375+ rehabilitation centers globally with 200 million cumulative patient steps and received FDA clearance for multiple sclerosis indications, expanding clinical scope. Ekso Bionics reported strong Q1 2022 unit bookings (23 units) and multi-unit orders from major healthcare networks. Novel exoskeleton designs showed clinical advantages—Chinese Ai-robot achieved 134m six-minute walk distance in 40-patient SCI trial vs. 48m with standard orthoses. However, critical evidence assessments identified persistent knowledge gaps on secondary health benefits and design/usability barriers limiting real-world applicability. Regulatory barriers intensified: CMS deferred pricing decisions to regional intermediaries, leaving reimbursement fragmented and uncertain, creating continued obstacles to mainstream adoption.
• 2022-H2: Neural-interface prosthetics advanced with peer-reviewed case studies showing RPNI with intramuscular electrodes improved grasp accuracy to 92.5% vs. 81.9% for surface controls, reducing cognitive load in multitasking scenarios. Vendor consolidation accelerated: Ekso Bionics acquired Parker Hannifin's Indego exoskeleton line in December, expanding institutional coverage to 400+ facilities and adding home-use product variants. Real-world deployments continued at regional healthcare centers (Bryan Health) with named patient successes. However, payer assessments documented persistent barriers—Blue Cross affiliates concluded evidence remained insufficient for net health outcome improvement, citing small study sizes and safety concerns. ReWalk reported Q3 revenue decline ($0.9M) due to delayed insurer coverage decisions, though submitted Medicare cases to regional MACs. Critical tension endured: strong institutional maturation and technical advancement contrasted against fragmented reimbursement, insufficient evidence by payer standards, and continued confinement to well-resourced rehabilitation settings.
• 2023-H1: Regulatory pathways advanced: ReWalk received FDA clearance for stairs and curbs functionality (expanding US home/community use cases), and CMS proposed including personal exoskeletons in the Medicare braces category for lump-sum payment (published June 30, 2023), signaling reimbursement progress. Clinical trials expanded evidence: home-based robotic gait training studies documented secondary vascular health benefits (reduced arterial stiffness) in chronic stroke patients, extending clinical justification beyond functional gain. Institutional deployment continued through philanthropic channels (SoldierStrong's 30th VA exoskeleton donation exemplified sustained adoption pathways). Research activity intensified with bibliometric analysis revealing significantly increasing publication volume (9,287 publications 2001-2020) and soft robotics emerging as highest-impact research focus. However, critical assessments highlighted persistent real-world barriers: user-centered reviews identified unresolved design limitations (safety, cost, weight, usability, appearance) and documented that soft robotic alternatives remained largely conceptual. Deployment remained concentrated in well-funded institutional and philanthropic settings; commercial adoption and Medicare coverage remained pending policy implementation.
• 2023-H2: CMS finalized Medicare reimbursement policy, setting preliminary payment of $94,617 for ReWalk systems and including personal exoskeletons in Medicare brace benefit category effective January 2024—major policy breakthrough enabling Medicare beneficiary access. Vendor consolidation matured: Ekso Bionics' Parker Hannifin acquisition expanded institutional portfolio to 400+ rehabilitation centers, demonstrating continued institutional adoption momentum. Neural-interface prosthetics advanced with novel hybrid bionic nerve interfaces combining RPNI with peripheral nerve recording, demonstrated in preclinical animal models over extended periods (29 weeks). Clinical reviews documented motion analysis systems (Lokomat, Armeo) as beneficial for objective gait assessment but highlighted persistent adoption barriers including reliability concerns and standardization gaps. Research topic editorials emphasized growing wearable robotics market expansion across hospital-to-home continuum with emerging soft exoskeletons and hybrid neuroprostheses as promising directions. However, vendor financial reports revealed significant sustainability challenges—major manufacturers reporting substantial operating losses and cash burn despite institutional deployment gains, indicating economic fragmentation persisting despite regulatory milestone. Soft robotic alternatives remained largely research-stage with adoption limited to conceptual designs.
• 2024-Q1: Medicare reimbursement policy implemented effective January 1, 2024, with first documented deployments including named patient case (LaTasha Washington, T8 paraplegic, using ReWalk Personal 6.0). PDAC issued official guidance confirming exoskeletons as braces under Medicare coverage. Research intensified on AI-driven control methodologies: systematic review analyzed 37 studies on AI in lower-limb exoskeletons, and Georgia Tech published universal control framework in Science Robotics enabling autonomous assistance adjustment without manual calibration. Novel reconfigurable hybrid exoskeleton-wheelchair designs showed promise in reducing muscular burden. However, Q1 SEC filings revealed stark vendor financial crisis: Ekso Bionics reported accumulated deficit of $242.6M with substantial doubt regarding going-concern status and negative operating cash flows, signaling fundamental viability challenges despite regulatory gains and institutional deployment expansion to 400+ centers. Critical tension: policy validation and technical advancement in AI control contrasted against vendor cash burn and unresolved market economics, highlighting gap between clinical efficacy and sustainable commercial adoption.
• 2024-Q2: Medicare coverage pathway for personal exoskeletons formalized in April, with ReWalk and Indego Personal establishing pricing and reimbursement clarity enabling broader access. Prosthetic research advanced on multiple fronts: adaptive control strategies using multi-sensor feedback improved grasp stability and expanded functional range, while biohybrid platforms integrating biological neural networks with artificial hands achieved 98% accuracy in neural encoding, advancing sensory restoration pathways. Bibliometric analysis of 1,034 exoskeleton rehabilitation studies (2014-2024) documented sustained research growth with field maturation from device development to AI/ML integration. Peer-reviewed editorial documented field-wide transition from rigid clinical devices to adaptive, user-centric soft, lightweight wearable systems. However, ethical review literature identified critical barriers to real-world adoption beyond technology: accident risk, deception risk, social isolation, liability, and data privacy concerns. By end-Q2, the field achieved technical and regulatory maturity while exposing persistent human-centered adoption constraints. Deployment remained concentrated in well-funded institutional and home settings with insurance support; cost structures, user training requirements, and psychosocial factors remained primary scaling barriers.
• 2024-Q3: Prosthetic advancement accelerated with MIT/Brigham publication in Nature Medicine demonstrating agonist-antagonist myoneural interface (AMI) surgery enabling full neural modulation of bionic leg prosthetics with biomimetic gait patterns in 7 patients—representing breakthrough in proprioceptive feedback integration for below-knee amputation. Exoskeleton efficacy evidence strengthened through multicenter RCT (92 stroke patients in China) showing statistically significant improvements in balance and gait with LiteStepper unilateral exoskeleton combined with conventional therapy. Real-world deployment demonstrated via named East Coast patient (T10 SCI, age 70) receiving Ekso Indego Personal for home use through new Medicare reimbursement pathway. Expert consensus recommendations from VA and vendor partners established clinical decision-making algorithms for personal exoskeleton community use, citing secondary health benefits (improved cardiovascular fitness, normalized bowel function) while noting persistent implementation knowledge gaps. Regulatory pathway maturation continued with documented patient access through insurance. By end-Q3, evidence of clinical efficacy and real-world deployment at national scale had solidified, though primary scaling barriers remained driven by economics, user training intensity, and psychosocial integration challenges rather than technical capability.
• 2024-Q4: Commercial adoption accelerated post-Medicare reimbursement: Ekso Bionics Q3 2024 results reported 33 EksoHealth devices sold ($4.1M revenue) with CMS Indego Personal reimbursement milestone achieved and 53.5% gross margins, confirming viable unit economics. Real-world Australian rehabilitation deployment showed 4,208 clinical uses of rehabilitation robotics with 269 patients over 12 months (65% physiotherapist-led), demonstrating scaled institutional integration across hospital-to-home continuum. Market analysis projected U.S. exoskeleton market growth from $234M (2025) to $640M (2033) at 13.09% CAGR with 18,000 annual SCI incident cases; Lifeward commercialized ReWalk 7 with cloud connectivity, signaling product ecosystem maturation. Global institutional deployment continued (200+ EksoGT centers, 400+ facilities post-acquisition, $15-200K regional pricing). However, critical barriers remained: practitioner-informed assessment documented persistent adoption friction (fit/comfort, cognitive training load, ROI justification, biomechanical misalignment) constraining mass-market deployment despite technical maturity and reimbursement progress. By Q4 2024, the category demonstrated strong institutional maturity (scaled deployment, viable reimbursement, multi-product ecosystem) yet faced structural scaling constraints rooted in device usability, implementation burden, and regional economic viability rather than technical feasibility.
• 2025-Q1: Brain-computer interface research advanced with UChicago-led studies demonstrating stable, localized tactile sensations via intracortical microstimulation enabling prosthetic users to perceive sensation of touch and shape. Long-term clinical data validated 5-year stability of implanted nerve cuffs (63% consistently responsive channels) for sensory restoration. Science Robotics published AI-driven prosthetic hand control combining motoneuron and postural synergies, achieving 82.5% target accuracy in prosthesis users. ReWalk 7 received FDA 510(k) clearance, continuing product ecosystem maturation. Clinical evidence strengthened: meta-analysis of 12 RCTs (651 stroke patients) showed robot-assisted training significantly improves motor function, walking, and balance. Critical assessment from Fit4MedRob Initiative identified persistent barriers to clinical implementation despite technological advancement, recommending large-scale pragmatic trials to establish cost-effectiveness and adoption pathways.
• 2025-Q2: Regulatory and reimbursement momentum accelerated: Ekso Indego received Australian TGA approval (April) expanding Asia-Pacific market access; ReWalk 7 secured first major commercial insurance approval (April), signaling expansion beyond Medicare beneficiaries to private insurance market covering two-thirds of SCI population. Administrative Law Judge ruling (June) established ReWalk as medically necessary, creating legal precedent for coverage decisions. Financial metrics show sustained but flat commercial adoption: Ekso Q1 2025 revenue $2.057M with $3.256M backlog, though Q2 comparison to Q2 2024 ($4.950M) revealed YoY revenue decline requiring strategic assessment. Implementation barriers persisted: physiotherapist qualitative study (April) documented persistent clinical adoption friction (usability, training burden, resource constraints) despite perceived benefits, indicating scaling barriers remain rooted in implementation complexity rather than technology maturity.
• 2025-Q3: Regulatory expansion accelerated globally: ReWalk 7 achieved CE mark approval (September) enabling European market access and German health insurance reimbursement, establishing three-region regulatory footprint (US/FDA, Australia/TGA, Europe/CE). Reimbursement pathways matured operationally: Lifeward received first Medicare Advantage Plan payment (September) confirming private insurance coverage with <30-day processing, complementing Medicare policy pathways. Financial performance revealed divergence: Ekso Bionics Q2 2025 reported revenue $2.1M (58% YoY decline) with gross margin compression to 40%, yet Personal Health products segment demonstrated 50%+ growth first-half 2025, indicating vendor portfolio restructuring toward home devices. Neural-interface prosthetics advanced: osseointegrated mechanoneural prostheses demonstrated improved walking, stair climbing, and embodiment in clinical trials, advancing sensory-feedback integration beyond lab benchmarks. Critical independent assessment emerged: Fit for Medical Robotics Initiative (July) identified persistent barriers to real-world adoption despite technological advancement—insufficient cost-effectiveness evidence, adoption resistance, and economic constraints limiting institutional implementation. Scaling remained concentrated in well-resourced settings; vendor financial stress persisted despite regulatory and reimbursement gains.
• 2025-Q4: Payer adoption reached critical scale: Humana and UnitedHealthcare granted prior authorization for ReWalk 7 (December), expanding coverage to 47% of 17M Medicare Advantage beneficiaries (8M new eligible users), transforming reimbursement from policy to commercial operation. Neural-interface prosthetics matured: machine learning-driven RPNI control achieved >96% accuracy in pose identification with real-time human functional task completion (peer-reviewed October publication); wireless osseointegrated neural interfaces demonstrated 8-week post-implantation functionality in pre-clinical models (November). Institutional deployment evidence strengthened: active randomized controlled trial with 120 acute stroke patients at Sunnyview Rehabilitation Hospital comparing Ekso exoskeleton to conventional therapy, ongoing at December update. SCIRE Professional's updated evidence review identified six FDA/CE-approved commercial exoskeletons with differentiated therapeutic/assistive categories. Application domain expansion: multi-institutional Chinese hospitals published evidence on exoskeleton applications in cancer rehabilitation with specific benefits (enhanced gait, muscle strength, psychological support) and telemedicine integration. Market projections documented $318.7M (2024) to $1.94B (2035) growth at 18.1% CAGR. Despite payer adoption scaling and technical maturity, structural barriers persisted: device fit/comfort, training complexity, cost-effectiveness justification, and regional economic divergence remained primary implementation constraints.
• 2026-Jan: Continued clinical evidence generation with advanced hybrid therapies: 12-month study combining percutaneous epidural stimulation with Ekso exoskeleton training demonstrated 85% protocol adherence in SCI patients, with adaptive assistance achieving higher step cadence and distance vs. fixed modes. Research identified critical biomechanical limitations: powered exoskeleton use reduced hip ROM and muscle activation while paradoxically decreasing 6-minute walk test performance, highlighting compensatory gait patterns and functional trade-offs in current device designs. Neural-interface innovation progressed: peer-reviewed PNAS publication demonstrated novel bioresorbable wireless neural interface for peripheral nerve injury therapy with successful 1-month in vivo healing in pre-clinical models, advancing peripheral nerve interface pathways for sensory restoration in prosthetics. Commercial deployment expanded: nearly 100 Wandercraft Atalante X units deployed across US, Europe, and Brazil rehabilitation institutions. Market analysis projected strong growth ($473M in 2025 to $2.71B by 2032, 28.6% CAGR) but highlighted persistent adoption barrier: average device cost of $42,800/unit. Co-design research with older adults and caregivers documented fundamental adoption constraints beyond cost—awareness gaps, reliability/safety concerns, and social norm resistance remained primary obstacles despite technical advancement.
• 2026-Feb: Payer adoption reached critical mass with Aetna joining Humana and UnitedHealthcare in prior authorization for ReWalk Personal (February), expanding coverage to ~16 million Medicare Advantage beneficiaries and enabling real-world patient access. However, independent qualitative research (JMIR, February) from 18 SCI patients and 26 healthcare professionals across Sweden and Spain documented persistent adoption barriers: practical constraints (awareness, access, cost), safety/reliability doubts, social norm apprehension, and competence concerns, indicating that expanded payer coverage alone insufficient for broader deployment without addressing device design and implementation complexity. Vendor financial distress deepened: Ekso Bionics reported 29% YoY revenue decline to $12.4M (2025), $11.7M net loss, and going-concern warning with <6 months operating runway; company executed strategic pivot merging into AI infrastructure firm (97% equity dilution), effectively exiting medical exoskeleton market—signaling fundamental market viability constraints independent of technical maturity or regulatory approval. Upper-limb rehabilitation innovation progressed: FDA-cleared IpsiHand brain-computer interface demonstrated clinically meaningful improvements in chronic stroke RCT (International Stroke Conference 2026); Lifeward announced acquisition of AI-powered Skelable upper-body exoskeleton (planned 18-24 month launch) targeting 4.6M addressable stroke population, indicating vendor portfolio expansion despite Ekso's market exit. Bibliometric analysis documented 20-year expansion of upper-limb rehabilitation robot research (2005-2025), confirming sustained academic engagement. By end-February 2026, the field achieved operational payer scaling and continued technical innovation in brain-computer interfaces and upper-limb systems, yet simultaneous vendor market exit and documented user-centered adoption barriers revealed deepening structural tension: expanded coverage and technical maturity created conditions for scaling, yet implementation burden, economic fragmentation, and psychosocial resistance remained primary constraints limiting real-world deployment beyond well-resourced institutional and home-care pathways.
• 2026-Apr: Brain-computer interfaces reached a regulatory milestone: China's NMPA granted the world's first commercial approval for an implantable BCI for hand movement control (Neuracle Medical Technology, validated across 32 patients at 11 hospitals), while a peer-reviewed meta-analysis of BCI-assisted stroke rehabilitation confirmed significant upper-limb functional improvement across 642 patients. Deployment momentum continued with Good Shepherd Rehabilitation surpassing 500,000 cumulative steps in Wandercraft Atalante X and Lifeward partnering with the top-ranked US rehabilitation hospital (Shirley Ryan AbilityLab) to expand ReWalk clinical integration. Countering the positive signals, a multicenter RCT found exoskeleton-assisted gait training was not superior to conventional rehabilitation for primary ambulatory outcomes, and seven leading exoskeleton researchers publicly identified unverified claims in sim-to-real transfer research — results violating physiological limits with unavailable code — highlighting persistent technical maturity gaps in ML-driven control systems.
• 2026-May: Ekso Bionics' formal exit from medical robotics was confirmed via SEC filing (ChronoScale Corporation business combination, ~97% shareholder dilution), formalizing a market viability signal that had been building since its Q1 2026 going-concern warning ($2.1M revenue, $6.9M net loss). BCI commercialization advanced on multiple fronts: CorTec's implanted device demonstrated dual therapeutic stimulation and thought-controlled computer use in a NIH-funded trial; BrainCo's non-invasive prosthetics reached 2,000 fittings in China at 1/5 to 1/7 Western device cost; and Paradromics gained FDA IDE approval for a speech-restoration trial across three academic centers. A soft exoskeleton RCT (n=56 Parkinson's patients) documented stride length gains of +0.15m and improved ankle dorsiflexion, while Lifeward's 13-year longitudinal registry showed zero fractures in the German exoskeleton cohort since 2018 — evidence that mature devices have resolved early safety concerns even as market economics remain fragile.